GlassScriptPhysician profile
Manuel S Cunanan
NPI 1144474636
$489,235.06
in general payments reported to CMS, 2019-2025
48 companies · $238K in 2025
The $238K reported for 2025 was more than what 99% of Pulmonary Disease providers received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,398 · 2020: $4,934 · 2021: $12K · 2022: $18K · 2023: $58K · 2024: $155K · 2025: $238K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $372K · Travel and Lodging: $29K · Food and Beverage: $23K · Honoraria: $15K · Consulting Fee: $13K · Education: $208.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $371,511.88 |
| Travel and Lodging | $29,147.27 |
| Food and Beverage | $22,883.42 |
| Honoraria | $15,200.00 |
| Consulting Fee | $13,158.75 |
| Education | $208.41 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $381,876.37 | 2019-2025 | Breztri, Fasenra, Tezspire |
| Genzyme Corporation | $32,017.94 | 2019-2025 | |
| Regeneron Healthcare Solutions, INC. | $19,083.77 | 2019-2025 | Dupixent |
| Grifols USA, LLC | $17,195.48 | 2020-2025 | Prolastin-C Liquid, Xembify |
| Verona Pharma, INC. | $17,176.84 | 2025 | Ohtuvayre |
| Optinose US, INC. | $9,908.01 | 2023-2025 | |
| Glaxosmithkline, LLC. | $2,980.58 | 2019-2025 | Nucala, Trelegy Ellipta, Arexvy |
| Philips North America LLC | $1,320.79 | 2019-2025 | (Ak6) Vest Therapy, Vest Therapy Und |
| Grifols Shared Services North America, INC. | $1,080.00 | 2023 | Prolastin-C Liquid |
| Boehringer Ingelheim Pharmaceuticals, INC. | $897.16 | 2019-2025 | Ofev, Spiriva Respimat, Stiolto Respimat |
| Ani Pharmaceuticals, INC. | $793.14 | 2022-2025 | Purified Cortrophin Gel |
| Mallinckrodt Hospital Products INC. | $731.23 | 2020-2025 | Acthar |
| Amgen INC. | $620.86 | 2021-2025 | Tezspire |
| Mylan Specialty L.P. | $602.49 | 2019-2024 | Yupelri |
| Insmed, INC. | $493.35 | 2020-2025 | Arikayce, Brinsupri |
Show all 48 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Manuel Cunanan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.